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Abstract
Background: This paper compiles data from different sources to get a first comprehensive picture
of psychometric and other methodological characteristics of the Menopause Rating Scale (MRS)
scale. The scale was designed and standardized as a self-administered scale to (a) to assess
symptoms/complaints of aging women under different conditions, (b) to evaluate the severity of
symptoms over time, and (c) to measure changes pre- and postmenopause replacement therapy.
The scale became widespread used (available in 10 languages).
Method: A large multinational survey (9 countries in 4 continents) from 2001/ 2002 is the basis
for in depth analyses on reliability and validity of the MRS. Additional small convenience samples
were used to get first impressions about test-retest reliability. The data were centrally analyzed.
Data from a postmarketing HRT study were used to estimate discriminative validity.
Results: Reliability measures (consistency and test-retest stability) were found to be good across
countries, although the sample size for test-retest reliability was small.
Validity: The internal structure of the MRS across countries was astonishingly similar to conclude
that the scale really measures the same phenomenon in symptomatic women. The sub-scores and
total score correlations were high (0.7–0.9) but lower among the sub-scales (0.5–0.7). This
however suggests that the subscales are not fully independent.
Norm values from different populations were presented showing that a direct comparison between
Europe and North America is possible, but caution recommended with comparisons of data from
Latin America and Indonesia. But this will not affect intra-individual comparisons within clinical
trials.
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The comparison with the Kupperman Index showed sufficiently good correlations, illustrating an
adept criterion-oriented validity. The same is true for the comparison with the generic quality-of-
life scale SF-36 where also a sufficiently close association has been shown.
Conclusion: The currently available methodological evidence points towards a high quality of the
MRS scale to measure and to compare HRQoL of aging women in different regions and over time,
it suggests a high reliability and high validity as far as the process of construct validation could be
completed yet.
Background
The interest of clinical research in aging women and males
increased in recent years and thereby the interest to meas-
ure health-related quality of life and symptoms. Women,
as do men, experience an age-related decline of physical
and mental capacity. They observe symptoms such as peri-
odic sweating or hot flushes, impaired memory, lack of
concentration, nervousness, depression, insomnia, and
bone – joint complaints.
The Menopause Rating Scale (MRS) is a health-related
quality of life scale (HRQoL) and was developed in
response to the lack of standardized scales to measure the
severity of aging-symptoms and their impact on the
HRQoL in the early 1990s. Actually, the first version of the
MRS was to be filled out by the treating physician but
methodological critics lead to a new scale which can easily
be completed by women, not by their physician [1,2].
The validation of the MRS started some years ago [2-6]
aiming at establishing an instrument to measure HRQoL
that can easily be completed. The aims of the MRS were
(1) to enable comparisons of the symptoms of aging
between groups of women under different conditions, (2)
to compare severity of symptoms over time, and (3) to
measure changes pre- and post-treatment [4-6]. The MRS
was formally standardized according to psychometric
rules and initially published in German [2]. During the
standardization of this instrument, three independent
dimensions were identified explaining 59% of the total
variance (factor analysis): psychological, somato-vegeta-
tive, and urogenital sub-scale. The MRS consists of a list of
11 items (symptoms or complaints). Each of the eleven
symptoms contained in the scale can get 0 (no com-
plaints) or up to 4 scoring points (severe symptoms)
depending on the severity of the complaints perceived by
the women completing the scale (an appropriate box is to
be ticked).
The scoring scheme is simple, i.e. the score increases point
by point with increasing severity of subjectively perceived
symptoms in each of the 11 items (severity 0 [no com-
plaints]...4 scoring points [very severe symptoms]). The
respondent provides her personal perception by checking
one of 5 possible boxes of "severity" for each of the items.
This can be seen in the questionnaires in the additional
files linked to this publication. The composite scores for
each of the dimensions (sub-scales) is based on adding up
the scores of each item of the respective dimensions. The
composite score (total score) is the sum of the dimension
scores. The three dimensions, their corresponding ques-
tions and the evaluation are detailed and summarized in
an attached file linked to this publication [see Additional
file 1].
The MRS scale became internationally well accepted. The
first translation was into English [7]. Other translations
followed [8], i.e. taking international methodological rec-
ommendations [9,10] into consideration. Currently, the
following versions are available: Brazilian, English,
French, German, Indonesian, Italian, Mexican/Argentine,
Spanish, Swedish, and Turkish language. These versions
are available in a published form, and can be downloaded
in PDF-format from the internet (see reference 8 and
http://www.menopause-rating-scale.info).
Like in other QoL scales, it is a challenge to satisfy the
demands of a clinical utility and outcomes sensitivity, and
this in addition to the conventional psychometric require-
ments of test reliability and validity.
The aim of this paper is to present additional psychomet-
ric data to discuss the methodologically relevant charac-
teristics of the MRS scale.
Methods
The development of the scale, instrument characteristics
(item selection, scaling), and norms and standardized
scores have been published elsewhere [2-5]. This applies
also for a few data that have been published on test-retest
stability and criterion-dependent validity [3,6].
During the last two years a number of smaller and larger
investigations were made from different groups to further
check methodological features of the scale. We performed
recently a large, multinational survey to represent the sit-
uation across nine countries and cultures using existing
and for the respective countries representative panels
between November 2001 and February 2002 to get infor-
mation about knowledge, attitudes and behaviour relatedHealth and Quality of Life Outcomes 2004, 2:45 http://www.hqlo.com/content/2/1/45
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to hormonal treatment in women aged 40–70 years:
Europe (Germany, France, Spain, Sweden), North America
(USA), Latin America (Mexico, Argentine, Brazil), and as
example for Asia  – Indonesia. Study participants were
accrued as a random sample of females aged 40 to 70
years from existing population panels. The sample size in
each of the countries was about 1000 females aged 40–70
years, with exception of USA (n = 1500). The participation
rates ranged between 46 and 94% across countries. The
demographic details of the sample are: On average, about
tertiles of the respondents were under 50 years, between
50–59, and over 60 years old in most of the countries,
however, about 50% were less than 50 years in Indonesia
and in Brazil. The majority of respondents reported a
Christian religion in Europe (range: 74% (Germany) to
96% (Spain), 85% in USA, and in Latin America (range:
95% (Argentina) to 97% (Mexico). The use of the MRS
was part of this survey, i.e. multinational data became
available to reconsider methodological issues more thor-
oughly such as internal structure of the scale, reliability
(internal consistency alpha), and reference values for dif-
ferent population.
For the purposes of reliability assessment we performed a
few preliminary studies with a test-retest approach. These
small, descriptive studies of community samples of
women aged 40–70 were done in summer and fall 2002
by local collaborators in the respective countries, but they
were done separately and independent from the main
study. These studies were done just for orientation with
convenience samples – not representative for the respec-
tive population.
There is only one intervention study (before and after hor-
monal treatment) available to our knowledge. This study
has been published [6] but not with regard to methodo-
logically relevant results of the MRS. These data will be
published soon.
With these data available, we were able to scrutinize many
methodological characteristics of the MRS scale to review




The assessment of scientific measurements depends first
of all on the evidence of replicability (consistency) and
test-retest reliability. In contrast to systematic and random
variation, reliability gives an estimate of method-related
measurement error which should be low not to hide or
dilute intended systematic changes – due to treatment for
example.
Table 1 show the internal consistency measured with
Cronbach's Alpha. The consistency coefficients range
between 0.6 and 0.9 across countries for the total score as
well the scores in the three domains. This is indicative for
a very acceptable consistency of the MRS scale in our opin-
ion. Moreover, there is no evidence that the scale works
different in so many different countries in four continents.
The test-retest correlation coefficients (Pearson's correla-
tion) support the suggestion of a good temporal stability
of the total scale and its three sub-scales (Table 2),
although most of the assessments across countries are
based on very small numbers and convenience samples
not claiming to be representative for the respective popu-
lation. The intention of these pilot studies was to get a pre-
liminary idea about retest stability. Larger sample sizes are
required to permit final conclusions for individual coun-
tries / languages.
The test-retest coefficients of the total score range between
0.8 and 0.96 across Europe, North and Latin America, and
Asia. When it comes to the subscales with much fewer
items, the variation increased and some of the coefficients
went down to 0.5 (urogenital domain in Indonesia). Alto-
gether, the test-retest stability over a time period of two
weeks aggregated at the international level supports the
notion of a very acceptable test-retest reliability of the
total scale and their three sub-scales.
Although there is an impressive set of information cur-
rently available concerning the reliability of the MRS
scale, there are also limitations: Small sample sizes pre-
vent a final conclusion regarding test-retest reliability in
some of the languages the scale has been translated in.
Validity
Similar to reliability which assesses the consistency of
measurement, the validity estimates if a scale measures
what it intends to measure. But whereas reliability can be
determined straight forward with very few indicators, the
validity is almost always a continuous process (construct
validation). It is a process of accumulating evidence for a
valid measurement of what is purposed. Therefore, the
currently available data are already fairly comprehensive
and do pave the way for a focussed and continuing valida-
tion process.
Internal structure of the MRS across countries
The first step of validation is usually to multivariately
demonstrate a similar internal structure ("dimensions")
of a given scale through factor analysis.
The first factorial analysis in 1996 was applied to identify
the dimensions of the scale. Three dimensions of symp-Health and Quality of Life Outcomes 2004, 2:45 http://www.hqlo.com/content/2/1/45
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toms/complaints were identified [2]: a psychological, a
somato-vegetative, and a urogenital factor that explained
58.8% of the total variance.
The recent large, multinational survey in nine countries of
four continents provided data to compare with the initial
standardisation sample of the MRS. The question was: Is
the internal structure of the MRS results comparable among
different countries or cultures. Astonishingly similar factor
loadings of the 11 items of the 3 domains of the MRS were
observed (Table 3). The same applies for the individual
countries of the respective regions (data not shown).
Although the prevalence of menopausal symptoms may
slightly differ among regions/cultures (see later), the struc-
ture of complaints/symptoms seems to be pretty much the
same. It suggests that the scale measures constantly the
same phenomenon which speaks in favour of the transla-
tion/cultural adaptation of the scale.
However, there are indications that the domains could be
somewhat overlapping and not as entirely independent as
the statistical model suggests: Muscle or joint problems got
a loading of 0.5 in the somatic and urogenital domain
(USA), and sleep disturbances both 0.5 in somatic and psy-
chological domain (Latin America). These two items had
similar problems in Spain, Mexico, and Brazil but not in
other countries (data not presented in table 3).
In clinical studies intra-individual comparisons over time
(before/after treatment) will be the main criterion which
might not be affected by potential slight differences in the
patient reported outcome structure. Therefore the general
agreement in the internal structure of the MRS scale across
country groups, even accepting the possibility of slight
differences in two items (cf. Table 3), suggests that the scale
can very well be used in clinical studies – even including
different countries.
Sub-scores and total score correlations
The relations among the sub-scales and the aggregate total
scale are patterns that are important in the methodological
assessment of a scale. In an ideal world, the correlations
between subscales (supposed to be independent due to the
statistical model) would be closer to 0 than the correlations
Table 1: Internal consistency coefficients (alpha) for the MRS scale across countries: total score and scores for the psychological, somatic, 
and urogenital domain. Data from the Nine-Country Study
International Europe North 
America
Latin America Asia
Total Overall Sweden Germany France Spain USA Overall Mexico Brazil Argentina Indonesia
N 9907 4465 1490 1050 941 984 1440 3002 1002 1000 1000 1000
Total score 0.83 0.86 0.85 0.84 0.86 0.86 0.88 0.86 0.87 0.86 0.83 0.84
Psychologic 
ascore
0.87 0.88 0.88 0.86 0.89 0.86 0.90 0.85 0.86 0.87 0.81 0.79
Somatic 
score
0.66 0.64 0.65 0.64 0.64 0.61 0.70 0.66 0.65 0.69 0.64 0.69
Urogenital 
score
0.65 0.65 0.64 0.63 0.67 0.67 0.70 0.60 0.62 0.55 0.62 0.65
Table 2: Test-retest coefficients (Pearson's correlation coefficient "r") for the MRS scale across countries: total score and scores for the 
psychological, somatic, and sexual sub-scale.
All Europe Latin America Asia
Overall Overall Germany UK France Spain Portugal Sweden Turkey Overall Argentina Brazil Overall Indonesia
N3 4 9 259 73 30 36 30 30 30 30 60 30 30 30 30
Total score 0,90 0,92 0,82 0,80 0,89 0,93 0,96 0,90 0,90 0,81 0,78 0,82 0,84 0,84
Psychological 
score
0,84 0,87 0,76 0,72 0,88 0,92 0,91 0,79 0,82 0,72 0,66 0,76 0,71 0,71
Somatic 
score
0,89 0,90 0,80 0,85 0,82 0,88 0,97 0,95 0,93 0,85 0,86 0,85 0,81 0,81
Urogen. 
score
0,86 0,89 0,77 0,82 0,94 0,98 0,95 0,87 0,89 0,73 0,67 0,74 0,50 0,50Health and Quality of Life Outcomes 2004, 2:45 http://www.hqlo.com/content/2/1/45
Page 5 of 8
(page number not for citation purposes)
with the construct of the aggregate total score to which all
sub-scales should significantly contribute. But that is the-
ory; Table 4 shows only somewhat lower correlations
among sub-scales (0.4–0.7) as compared with correlation
of sub-scales with the total score (0.7–0.9). This is less dif-
ferent than one would have wished. It suggests that the
sub-scales are not as independent from each other as one
would expect them to be – based on a factorial analysis
with orthogonal factors. The situation was similar in the
four regions listed in Table 4 and in the individual coun-
tries belonging to these regions. It is important to realize
how similar these correlation coefficients are among
countries/aggregates. This is suggestive of pretty similar
features of the MRS scale across the countries of this
review.
Compatibility of MRS reference values for different 
population
There are different categories of severity of complaints or
problems with QoL. For the comparison of these catego-
ries across countries or cultures it is important to under-
stand the prevalence of complaints. Currently, there is
only one table with reference values and definitions pub-
lished – for the German population from the initial stand-
ardization of the MRS [2]. Are these reference values
applicable for other countries/cultures?
The data of our large multicultural survey permitted such
comparisons. The mean values (SD) of the MRS total
score and the three domains are depicted in Table 5. The
mean values of the total score and the 3 domain scores are
not statistically significantly different between Europe and
North America. Thus, there is no evidence yet to exclude
direct comparisons of MRS values between these regions.
However, the total, psychological and somatic scores were
systematically higher in Latin America, and systematically
(significantly) lower in Asia (Indonesia) than in Europe/
North America. The urogenital scores were significantly
lower in Latin America/Indonesia than in Europe/US.
Obviously the perception of the prevalent symptoms
depends on cultural factors – or the symptoms show real
differences in prevalence. Thus, direct comparisons of
MRS scores between Europe/North America on the one
side and regions in Latin America and Asia cannot are not
recommended. This does not effect intra-individual com-
parisons (e.g., pre/ post therapy) within these countries
and it may also very little affect the comparison of relative
changes (pre/post treatment) among different countries.
The latter is a hypothesis and needs further evidence form
research/experience.
Similar mean values could still have a different distribu-
tion across the proposed four categories of "severity of
Table 3: Internal structure of the MRS scale across countries in 9 countries of four continents (2002) compared with the initial analysis 
of a German sample in 1996. Principal component analysis, Varimax rotation. Complaints (item number in MRS), numbers, and country 
groups. Only factor loadings ≥ 0.5 are shown.
Complaints (item number)
N Flushes(1) Heart(2) Sleep(3) Joints(11) Depress(4) Irritabil(5) Anxiety(6) Exhaust(7) Sexual(8) Bladder(9) Dryness(10)
Germany, 1996 479
somatic 0.8 0.7 0.6 0.5
psychologic 0.8 0.7 0.8 0.6
urogenital 0.7 0.8 0.8
All countries, 2002 10297
somatic 0.7 0.8 0.5 0.5
psychologic 0.8 0.8 0.8 0.7
urogenital 0.7 0.6 0.8
Europe, 2002 4791
somatic 0.7 0.7 0.6 0.6
psychologic 0.8 0.9 0.8 0.6
urogenital 0.7 0.6 0.8
N.-America (USA) 1500
somatic 0.7 0.7 0.7 0.5
psychologic 0.8 0.9 0.8 0.6
urogenital 0.5 0.8 0.6 0.8
Latin America, 2002 3006
somatic 0.5 0.9 0.5 0.4
psychologic 0.5 0.8 0.8 0.8 0.7
urogenital 0.6 0.7 0.8
Asia (Indonesia) 1000
somatic 0.9 0.6 0.5 0.5
psychologic 0.8 0.8 0.8 0.5
urogenital 0.8 0.5 0.9Health and Quality of Life Outcomes 2004, 2:45 http://www.hqlo.com/content/2/1/45
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complaints": no/little symptoms, mild, moderate, and
severe complaints, i.e. for the total scale and the three
domains. The prevalence of these categories across the
four regions studied is seen in Table 6. The comparison of
the prevalence (and 95% confidence interval) showed
that the above discussed differences between Europe/US
and Latin-America or Indonesia very much depend on the
severity of complaints. Whereas the differences in the psy-
chological domain were less impressive, the dissimilarity
was most pronounced in the urogenital domain and less
also in the somatic domain. Whether this is due to differ-
ent perception of identical symptoms (differences in the
appearance of symptoms or both) remains a speculation.
This however needs to be considered when direct compar-
isons among different cultures are intended. The
prevalence of different "degrees of severity" of menopau-
sal symptoms measured with the MRS was found to be
almost identical in the aggregate of Europe and North
America.
Criterion-oriented validity: correlation with other scales
In fact, the comparison with other scales of similar pur-
pose is important. It is known from other quality of life
scales that comparisons with scales with similar purposes
are much more important than comparisons with so-
called objective parameters such as exercise tests, physio-
logical or chemical parameters – in our case with
hormones.
Health related quality of life should be validated against
quality of life measured with other generic QoL scales
(e.g., SF-36), and against specific instruments to measure
symptoms in aging women (e.g. Kupperman index).
These data were published elsewhere [6,11] but will be
briefly summarized in the context of this review.
Kupperman Index
Although the Kupperman Index was not validated accord-
ing to psychometric standards it is still in use in the med-
ical practice to monitor menopausal symptoms. Therefore
a comparison with the fully standardized MRS seems to be
Table 4: Domain score – total score correlations of the MRS scale across four country groups. Community samples.
Domains
Psychological score Somatic score Urogenital score
Europe (n = 4246)
Total score 0.9 0.9 0.7
Psychological score -- 0.6 0.5
Somatic score -- -- 0.5
North America (n = 1376)
Total score 0.9 0.9 0.8
Psychological score -- 0.7 0.5
Somatic score -- -- 0.5
Latin America (n = 3001)
Total score 0.9 0.9 0.7
Psychological score -- 0.7 0.5
Somatic score -- -- 0.5
Asia (n = 1000)
Total score 0.9 0.9 0.7
Psychological score -- 0.7 0.4
Somatic score -- -- 0.4
Table 5: Mean values and standard deviation of MRS total score and 3 domains. Results from a large, multinational survey (see methods)
Total score Psychological Score Somato-vegetative Score Urogenital Score
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
Europe 4246 8.8 (7.1) 4453 3.4 (3.4) 4465 3.6 (2.9) 4465 1.9 (2.2)
N.-America 
(USA)
1376 9.1 (7.6) 1426 3.4 (3.5) 1440 3.8 (3.1) 1437 2.0 (2.3)
Lat.-America 3001 10.4 (8.8) 3002 4.9 (4.5) 3006 4.1 (3.6) 3005 1.4 (2.2)
Asia 1000 7.2 (6.0) 1000 2.9 (2.9) 1000 3.3 (2.7) 1000 1.0 (1.6)Health and Quality of Life Outcomes 2004, 2:45 http://www.hqlo.com/content/2/1/45
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reasonable. If one divides the distribution of both scales
into quartiles and compares the frequencies, both instru-
ments were found to be closely associated: Kendall's tau-
b coefficient 0.75 (95% CI 0.71–0.80) [6]. Similar was the
Pearson correlation coefficient with r= 0.91(95% CI 0.89–
0.93). The two scales can be regarded as measuring the
same phenomena. However, some methodological prob-
lems of the Kupperman Index were identified in this com-
parison (see [6] for details).
Generic QoL Scale SF-36
Two sub-scales of the multi-domain quality of life scale
SF-36 was compared with the MRS: the somatic sum score
(with somatic domain of MRS) and the psychologic sub-
scales of both instruments. Both somatic domains were
sufficiently well and significantly associated: Kendall's
tau-b = 0.43 (95% CI 0.52–0.35); Pearson correlation
coefficient r= 0.48 (95% CI 0.58–0.37). That means, the
higher the score in the somatic dimension of the MRS, the
lower the quality of life according to the somatic sum-
score of the SF-36 [6,11]. Similar was the results of the
comparison of the psychological scores of both instru-
ments: Kendall's tau-b = 0.49 (95% CI 0.56–0.41); Pear-
son correlation coefficient r= 0.73 (95% CI 0.81–0.65).
Discriminative validity
i.e., the ability of the scale to accurately measure treatment
effects and to predict the clinically based assessment of
physicians, was not analysed so far. At present, there is
one post-marketing study that can be used to preliminary
assess discriminative validity. The results will be pub-
lished soon elsewhere. To this end, many clinicians
understand the term "validity" and mean high utility for
clinical work or research.
Conclusions
The MRS scale is a standardized HRQoL scale with good
psychometric characteristics. The use in many countries
offered the possibility to compare the test characteristics
across countries. Reliability measures (consistency and
test-retest stability) were found to be good in all countries
where data were obtained – however, some samples were
very small and therefore considered as preliminary
information.
The validity was measured in its various forms: The inter-
nal structure of the MRS across countries was sufficiently
similar to conclude that the scale really measures the same
phenomenon in women with complaints. The sub-sores
and total score correlations showed high coefficients with
the total score and less among the sub-scales. This how-
ever indicates that the subscales are not fully independent
in practice.
Comparisons of reference values from different popula-
tions showed that the MRS scores can easily be compared
between Europe and North America/US. Direct compari-
sons between Europe/North America and Latin American
Table 6: Comparison of "degree of severity" of the MRS and its domains. Prevalence in percent (%) and 95% confidence interval (in 
parenthesis) in the population sample studied in the respective regions (see methods)
Europe North America Latin America Asia
Total score
No, little (0–4) 28.8 (+/-1.3) 28.0 (+/-2.3) 31.0 (+/-1.7) 40.2 (+/-3.0)
Mild (5–8) 21.9 (+/- 1.2) 23.9 (+/-2.2) 20.2 (+/-1.4) 27.5 (+/-2.8)
Moderate (9–16) 25.1 (+/-1.2) 25.7 (+/-2.2) 26.2 (+/-1.6) 22.8 (+/-2.6)
Severe (17+) 24.3 (+/- 1.2) 22.5 (+/-2.1) 22.7 (+/-1.5) 9.5 (+/-1.8)
Psychological domain
No, little (0–1) 35.4 (+/-1.4) 36.8 (+/-2.4) 36.8 (+/-1.6) 41.3 (+/-3.1)
Mild (2–3) 21.8 (+/-1.2) 21.9 (+/-2.1) 21.9 (+/-1.4) 25.4 (+/-2.7)
Moderate (4–6) 19.5 (+/-1.1) 18.7 (+/-2.0) 18.7 (+/-1.4) 21.3 (+/-2.6)
Severe (7+) 23.4 (+/-1.2) 22.5 (+/-2.1) 22.5 (+/-1.7) 12.0 (+/-2.0)
Somato-vegetative 
domain
No, little (0–2) 39.5 (+/-1.4) 37.9 (+/-2.4) 42.1 (+/-1.8) 46.8 (+/-3.1)
Mild (3–4) 22.6 (+/-1.2) 25.6 (+/-2.2) 19.4 (+/-1.4) 27.0 (+/-2.8)
Moderate (5–8) 24.2 (+/-1.2) 24.3 (+/-2.2) 25.6 (+/-1.6) 20.8 (+/-2.5)
Severe (9+) 13.7 (+/-1.0) 12.1 (+/-1.7) 12.9 (+/-1.2) 5.4 (+/-1.4)
Urogenital domain
No, little (0) 34.3 (+/-1.3) 33.4 (+/-2.4) 28.2 (+/-1.8) 55.6 (+/-3.1)
Mild (1) 17.2 (+/-1.1) 17.0 (+/-2.0) 18.6 (+/-1.1) 18.6 (+/-2.4)
Moderate (2–3) 23.0 (+/- 1.2) 24.2 (+/-2.2) 21.8 (+/-1.3) 17.0 (+/-2.3)
Severe (4+) 25.6 (+/-1.2) 25.4 (+/-2.2) 31.4 (+/-1.3) 8.8 (+/-1.8)Publish with BioMed Central    and   every 
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countries and Asia (Indonesia) should be considered with
caution because the severity of reported symptoms seems
to differ. The reasons are not clear, further research is
needed.
The comparison with other scales for menopausal symp-
toms (Kupperman Index) showed a sufficiently close
association and correlation coefficients, i.e. illustrating a
good criterion-oriented validity. The same is true for the
comparison with the generic QoL scale SF-36 where also
high correlation coefficients have been shown.
Thus, the currently available methodological evidence
points towards a high quality of the MRS scale to measure
and to compare HRQoL of aging males over time or inter-
vention. It suggests a high reliability and high validity as
far as the process of construct validation could be
completed.
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